Sustained antidepressant effect of PEA replacement - PubMed (original) (raw)
Case Reports
. 1996 Spring;8(2):168-71.
doi: 10.1176/jnp.8.2.168.
Affiliations
- PMID: 9081552
- DOI: 10.1176/jnp.8.2.168
Case Reports
Sustained antidepressant effect of PEA replacement
H Sabelli et al. J Neuropsychiatry Clin Neurosci. 1996 Spring.
Abstract
Phenylethylamine (PEA), an endogenous neuroamine, increases attention and activity in animals and has been shown to relieve depression in 60% of depressed patients. It has been proposed that PEA deficit may be the cause of a common form of depressive illness. Fourteen patients with major depressive episodes that responded to PEA treatment (10-60 mg orally per day, with 10 mg/day selegiline to prevent rapid PEA destruction) were reexamined 20 to 50 weeks later. The antidepressant response had been maintained in 12 patients. Effective dosage did not change with time. There were no apparent side effects. PEA produces sustained relief of depression in a significant number of patients, including some unresponsive to the standard treatments. PEA improves mood as rapidly as amphetamine but does not produce tolerance.
Similar articles
- Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study.
Alevizos B, Alevizos E, Leonardou A, Zervas I. Alevizos B, et al. Psychiatriki. 2012 Apr-Jun;23(2):143-8. Psychiatriki. 2012. PMID: 22796912 Clinical Trial. - Lithium potentiation of antidepressant treatment.
Louie AK, Meltzer HY. Louie AK, et al. J Clin Psychopharmacol. 1984 Dec;4(6):316-21. J Clin Psychopharmacol. 1984. PMID: 6511998 - A Belgian multicentre study of fluvoxamine in depressive outpatients.
Brasseur R, Van Moffaert M, Mesotten F, Ansseau M, Uytdenhoef P, Bartholome F. Brasseur R, et al. Acta Psychiatr Belg. 1985 Sep-Oct;85(5):636-43. Acta Psychiatr Belg. 1985. PMID: 3937441 - Translating depression biomarkers for improved targeted therapies.
Bredt DS, Furey ML, Chen G, Lovenberg T, Drevets WC, Manji HK. Bredt DS, et al. Neurosci Biobehav Rev. 2015 Dec;59:1-15. doi: 10.1016/j.neubiorev.2015.09.013. Epub 2015 Oct 1. Neurosci Biobehav Rev. 2015. PMID: 26432926 Review. - Phenylethylamine in neuropsychiatric disorders.
Wolf ME, Mosnaim AD. Wolf ME, et al. Gen Pharmacol. 1983;14(4):385-90. doi: 10.1016/0306-3623(83)90020-4. Gen Pharmacol. 1983. PMID: 6352395 Review.
Cited by
- Spasmolytic Effects of Aphanizomenon Flos Aquae (AFA) Extract on the Human Colon Contractility.
Amato A, Terzo S, Marchesa P, Maffongelli A, Martorana M, Scoglio S, Mulè F. Amato A, et al. Nutrients. 2021 Sep 28;13(10):3445. doi: 10.3390/nu13103445. Nutrients. 2021. PMID: 34684446 Free PMC article. - Novel Molecular Targets of Antidepressants.
Jarończyk M, Walory J. Jarończyk M, et al. Molecules. 2022 Jan 14;27(2):533. doi: 10.3390/molecules27020533. Molecules. 2022. PMID: 35056845 Free PMC article. Review. - Exercise and bipolar disorder: a review of neurobiological mediators.
Alsuwaidan MT, Kucyi A, Law CW, McIntyre RS. Alsuwaidan MT, et al. Neuromolecular Med. 2009;11(4):328-36. doi: 10.1007/s12017-009-8079-9. Neuromolecular Med. 2009. PMID: 19649751 Review. - Effects of the Aphanizomenon flos-aquae Extract (Klamin®) on a Neurodegeneration Cellular Model.
Nuzzo D, Presti G, Picone P, Galizzi G, Gulotta E, Giuliano S, Mannino C, Gambino V, Scoglio S, Di Carlo M. Nuzzo D, et al. Oxid Med Cell Longev. 2018 Sep 17;2018:9089016. doi: 10.1155/2018/9089016. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30310529 Free PMC article. - β-phenethylamine--a phenylalanine derivative in brain--contributes to oxidative stress by inhibiting mitochondrial complexes and DT-diaphorase: an in silico study.
Mazumder MK, Paul R, Borah A. Mazumder MK, et al. CNS Neurosci Ther. 2013 Aug;19(8):596-602. doi: 10.1111/cns.12113. Epub 2013 May 3. CNS Neurosci Ther. 2013. PMID: 23638910 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical